Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 2,003 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Discrete Clear all

Conditions: Cognitive Control
Interventions: iTBS then cTBS, cTBS then iTBS; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 40 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: D-serine, placebo, Sensory Based remediation paradigm; Drug · Behavioral
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 64 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: HIV-1
Interventions: D/C/F/TAF FDC placebo; Drug
Lead sponsor: Janssen Pharmaceutica N.V., Belgium; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more

Conditions: Bipolar Disorder, Depression
Interventions: IPSRT plus placebo (IPSRT-PLA), IPSRT plus quetiapine; Drug
Lead sponsor: Holly Swartz; Other
Eligibility: 18 Years to 65 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Urolithiasis, Kidney Stone, Kidney Stones
Interventions: CVAC® SYSTEM, FLEXIBLE AND NAVIGATIONAL URETERAL ACCESS SHEATH (FANS) IN FLEXIBLE URETEROSCOPY (FURS); Device
Lead sponsor: Calyxo, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Amniotic Band Syndrome, Upper Extremity Deformities, Congenital
Interventions: 3D Printed Upper-limb Prosthesis, Home Intervention; Device · Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 3 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Coronavirus, Covid19
Interventions: bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4,044 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 207
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more

Conditions: Post Partum Depression
Interventions: iTBS; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hypotension, Spinal Cord Injury
Interventions: N-Nitro L-arginine-methylester (L-NAME), Head-up Tilt maneuver; Drug · Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Fibrodysplasia Ossificans Progressiva
Interventions: Palovarotene, midazolam; Drug
Lead sponsor: Clementia Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Myelodysplastic Syndromes
Interventions: LB-100; Drug
Lead sponsor: Lixte Biotechnology Holdings, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Obesity
Interventions: Parent-only Group, Parent + Child Group; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 8 Years to 12 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Diabetes Mellitus, Type 1
Interventions: Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin, Daclizumab or basiliximab, Sirolimus, Tacrolimus, Etanercept; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota

Conditions: Prostate Cancer
Interventions: flutamide, Zoladex, Lupron, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 2,028 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2018
U.S. locations: 222
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 173 more

Conditions: Hepatitis B, Hepatitis C, HIV, HIV Infections
Interventions: NCMIT, SCMIT; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 39 Years · Male only
Enrollment: 451 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Clinical Trials
Interventions: Discrete choice experiment; Other
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 801 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: eszopiclone, zolpidem, placebo; Drug
Lead sponsor: Kettering Health Network; Other
Eligibility: 18 Years to 35 Years · Male only
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Kettering, Ohio

Conditions: Healthy
Interventions: K-001, K-877-ER, CSG452; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: ADHD
Interventions: Classroom Behavior Support (CBS) Condition, Standard Problem Solving Consultation; Behavioral
Lead sponsor: Ohio University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: Sickle Cell Disease, Vaso-Occlusive Crisis
Interventions: Ketamine; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 10 Years to 25 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Oakland, California

Conditions: Tendinosis, Tendinitis
Interventions: Tenotomy (no injection), Ultrasound guided platelet rich plasma injection; Procedure · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Non-Small Cell Lung Cancer (NSCLC), Small-Cell Lung Cancer (SCLC)
Interventions: Blood Draw; Other
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 945 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 23
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 20 more

Conditions: Severe Asthma
Interventions: Verekitug, Placebo; Drug
Lead sponsor: Upstream Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 28
States / cities: Bakersfield, California • Northridge, California • Upland, California + 21 more

Conditions: Pneumococcal Conjugate Vaccine
Interventions: 13-valent Pneumoccocal Conjugate Vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 5
States / cities: Birmingham, Alabama • Louisville, Kentucky • The Bronx, New York + 1 more

Search by objective public record fields.

Measuring Plasticity in SFC/dACC Following Theta-Burst-Stimulation Using TMS

N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

Acute Psychotherapy for Bipolar II Depression

A Retrospective, Multi-center Real-world Study of Steerable Ureteroscopic Renal Evacuation (SURE) Procedure With the CVAC® System

The Influence of 3D Printed Prostheses on Neural Activation Patterns

ACTIV-2: A Study for Outpatients With COVID-19

Accelerated iTBS for Post Partum Depression

Prevention of Low Blood Pressure in Persons With Tetraplegia

Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects

A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Parents as the Agent of Change for Childhood Obesity

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV

Clinical Trial Preference Study

Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem

Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452

Classroom Behavior Support (CBS) Project

Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis

A Prospective Comparison of Ultrasound-Guided Percutaneous Platelet-Rich Plasma Injection

Prospective Clinicogenomic Program

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease